Cost-effectiveness of alternative thresholds of the fasting plasma glucose test to identify the target population for type 2 diabetes prevention in adults aged ≥45 years

Diabetes Care

Volumn 36, Issue 12, 2013, Pages 3992-3998

  Zhuo, Xiaohui ^a   Zhang, Ping ^a   Kahn, Henry S ^a   Gregg, Edward W ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; UNIVARIATE ANALYSIS; BLOOD; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; ECONOMICS; FEMALE; LIFESTYLE; MALE; METABOLISM; MIDDLE AGED; NUTRITION; PHYSIOLOGY; PROCEDURES; STATISTICAL MODEL; UNITED STATES;

GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; MODELS, ECONOMIC; NUTRITION SURVEYS; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 84891878012     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0497     Document Type: Article

References (43)

1. Heianza Y, Hara S, Arase Y, et al. HbA1c 5z7-6z4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet 2011;378:147-155
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36(Suppl 1):S67-S74
3. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation [report online], 2006. Geneva, Switzerland, World Health Organization. Available from http://www.who.int/ diabetes/publications/Definition%20and%20diagnosis%20of% 20diabetes-new.pdf. Accessed 8 August 2013
4. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
5. National Diabetes Prevention Program [Internet], 2012. Atlanta, Georgia, Centers for Disease Control and Prevention. Available from http://www.cdc.gov/ diabetes/prevention/index.htm. Accessed June 2012
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62-S69
7. Forouhi NG, Balkau B, Borch-Johnsen K, et al.; EDEG. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia 2006;49: 822-827
8. Lawes CM, Parag V, Bennett DA, et al.; Asia Pacific Cohort Studies Collaboration. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004;27:2836-2842
9. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164:2147-2155
10. Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005;28:2626-2632
11. Hoerger TJ, Segel JE, Zhang P, Sorensen SW. Validation of the CDC-RTI diabetes cost-effectiveness model [report online], 2009.. Research Triangle Park, North Carolina, RTI International. Available from http://www.rti.org/pubs/ mr-0013-0909-hoerger.pdf. Accessed 8 August 2013
12. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140: 689-699
13. Hoerger TJ, Hicks KA, Sorensen SW, et al. Cost-effectiveness of screening for prediabetes among overweight and obese U.S. adults. Diabetes Care 2007;30:2874-2879
14. Herman WH, Hoerger TJ, Brandle M, et al.; Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323-332
15. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-2551
16. Centers for Disease Control and Prevention. N.C.f.H.S., Division of Health Interview Statistics. Distribution of age at diagnosis of diabetes among adult incident cases aged 18-79 years, United States, 2011. Available from http://www .cdc.gov/diabetes/statistics/age/fig1.htm. Accessed 23 September 2013
17. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-811
18. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 2001;285:2109-2113
19. Balkau B, Hillier T, Vierron E, et al. Comment to: Borch-Johnsen K, Colagiuri S, Balkau B et al. (2004) Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47:1396-1402. Diabetologia 2005;48:801-802
20. Tirosh A, Shai I, Tekes-Manova D, et al.; Israeli Diabetes Research Group. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005;353:1454-1462
21. Qiao Q, Lindström J, Valle TT, Tuomilehto J. Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. Diabet Med 2003;20: 1027-1033
22. Wareham NJ, Byrne CD, Williams R, Day NE, Hales CN. Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care 1999;22: 262-270
23. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352: 837-853
24. Levitzky YS, Pencina MJ, D'Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J AmColl Cardiol 2008; 51:264-270
25. Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension 2002; 40:679-686
26. Lee M, Saver JL, Hong KS, Song S, Chang KH, Ovbiagele B. Effect of pre-diabetes on future risk of stroke: meta-analysis. BMJ 2012;344:e3564
27. Gans KM, Lapane KL, Lasater TM, Carleton RA. Effects of intervention on compliance to referral and lifestyle recommendations given at cholesterol screening programs. Am J Prev Med 1994;10:275-282
28. Burke LE, Dunbar-Jacob JM, Hill MN. Compliance with cardiovascular disease prevention strategies: a review of the research. Ann Behav Med 1997;19:239-263
29. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143: 251-264
30. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003;26:2518-2523
31. Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238-2243
32. Gold M, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York, Oxford University Press, 1996
33. Ackermann RT, Marrero DG. Adapting the Diabetes Prevention Program lifestyle intervention for delivery in the community: the YMCA model. Diabetes Educ 2007;33:69, 74-75, 77-78
34. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med 2008;35:357-363
35. Diabetes Prevention Program Research Group; Knowler WC, Fowler SE, Hamman RF, et al. 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-1686
36. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of costeffectiveness acceptability curves. Health Econ 2001;10:779-787
37. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8:165-178
38. Cheng C, Kushner H, Falkner BE. The utility of fasting glucose for detection of prediabetes. Metabolism 2006;55:434-438
39. Kahn HS, Cheng YJ, Thompson TJ, Imperatore G, Gregg EW. Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years. Ann Intern Med 2009;150:741-751
40. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middleaged adults: the Framingham Offspring Study. Arch Intern Med 2007;167:1068-1074
41. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002;25:1862-1868
42. Stevens VJ, Obarzanek E, Cook NR et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001;134:1-11
43. Ratner R, Goldberg R, Haffner S et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005;28:888-894